Domain Therapeutics Rebrands, Introduces New Name and Logo

Kainova Therapeutics, a company specialising in treatments for patients in immuno-oncology and inflammation, has revealed its rebranding to "Kainova Therapeutics".

"The name 'Kainova' combines 'Kairos', the opportune or decisive moment, and 'Nova', symbolising innovation and renewal," says the Canadian biopharmaceutical firm.

Adding: "It embodies the company's transformation and ambition, reflecting its drive to innovate, determination to deliver, and commitment to therapies that truly transform lives."

"The rebrand is not a break from our scientific or strategic roots; it is the clearer expression of who we are today and the impact we strive to deliver for patients," further comments Kainova Therapeutics' CEO, Sean A. MacDonald.

The company, based in Montreal, is focused on creating immunotherapies that utilise the immune system to combat cancer, particularly aiming at G Protein-Coupled Receptors (GPCRs).

These receptors are considered crucial targets in contemporary medicine, with around 36% of available pharmaceuticals directly aimed at them.

Source: Kainova Therapeutics